drugset
drugset / Trial / NCT05011474

Safety and Efficacy Study of Matrilin-3 Pretreated Autologous Adipose Derived Mesenchymal Stem Cells Implantation in Chronic Low Back Pain Patients With Lumbar Intervertebral Disc Degeneration

NCT05011474 ↗

Phase 1/2 Unknown 4 enrolled Inbo Han
NaSingle-groupOpen-labelTreatment

Summary

To investigate the safety and efficacy of autologous adipose-derived mesenchymal stem cell spheroids pretreated with matrillin-3 in chronic low back pain patients with lumbar intervertebral disc degeneration.

Timeline

Start
2021-04-23
Primary completion
2022-01-20
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject autologous adipose-derived mesenchymal stem cell spheroid Cell therapy — —

Indications

lumbar disk degenerative disorder